AMPlifying targets

Although small- and medium-sized biotechs are absent from the NIH's new Accelerating Medicines Partnership with industry and not-for-profit organizations, consortium leaders expect that making results publicly available on their search for new targets and biomarkers in four diseases will benefit all players. However, it is unclear whether the $230 million, 5-year fund is adequately financed to meet the partnership's goal of accelerating target discovery.

The public-private partnership (PPP) includes 10 companies, ...